You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.

This drug entry is a stub and has not been fully annotated. It was added on November 30, 2015 and is scheduled to be annotated soon.

Identification
NameMagnesium carbonate
Accession NumberDB09481
TypeSmall Molecule
GroupsApproved
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cepasium Tab 100mgTablet100 mgOralLaboratoires Cortunon Inc.1979-12-312002-08-23Canada
Humco Dewees CarminativeSuspension50 mg/mLOralHumco Holding Group. Inc.1998-03-25Not applicableUs
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Acid Gone AntacidMajor
Acid Gone Antacid Extra StrengthMajor
Aluminum Hydroxide and Magnesium CarbonateSimpex Pharma Pvt. Ltd
AntacidMeijer Distribution
Antacid - TabSwiss Herbal Remedies Ltd.
Antacid Extra StrengthRite Aid
Aspirin Plus Stomach Guard Ext.stgth.capletSterling Winthrop Inc.
Aspirin Plus Stomach Guard Extra StrengthBayer Inc Consumer Care
Aspirin Plus Stomach Guard TabSterling Winthrop Inc.
Aspirin With Stomach GuardBayer Inc Consumer Care
Aspirin With Stomach Guard Extra Strength - TabBayer Inc Consumer Care
Calcium and Magnesium TabCountry Health Laboratories Ltd.
Cvs Health Extra Strength Heartburn Relief Antacid Original FlavorCvs Health
Equate Antacid Extra StrengthWalmart Stores
Equate Extra Strength AntacidWalmart Stores
EstomarolLaboratorios Imperiales, S.A. De C.V.
Foamcoat AntacidGuardian Drug Company
Gavis-care AntacidGericare Pharmaceuticals
GavisconGlaxo Smith Kline Consumer Healthcare Holdings (Us) Llc
Gaviscon Extra StrengthGlaxo Smith Kline Consumer Heathcare Lp
Good Neighbor Pharmacy Antacid Extra StrengthAmerisource Bergen
InonSato Pharmaceutical
Leader Antacid Extra StrengthCardinal Health
Maalox Antacid CapletsRhone Poulenc Rorer
Magnebind 400 RxNephro Tech, Inc.
Magnesium Comprime TabHerbes Universelles Inc.
RenacidinUnited Guardian, Inc.
Riginic Antacid LiquidRij Pharmaceutical Corporation
Rx Act Antacid Extra StrengthH.E.B.
Sohmed Acid ReducerSOHM Inc.
Stomachin AntacidChang Kuo Chou Pharmaceutical Co. Ltd.
Sunmark Antacid Extra StrengthMc Kesson
Tri-buffered Asa TabZee Medical Inc
SaltsNot Available
Categories
UNII0E53J927NA
CAS numberNot Available
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Pharmacology
IndicationNot yet annotated
PharmacodynamicsNot yet annotated
Mechanism of actionNot yet annotated
Related Articles
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Magnesium carbonate.Investigational
19-norandrostenedioneThe bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium carbonate.Experimental, Illicit
2,5-Dimethoxy-4-ethylamphetamineMagnesium carbonate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental, Illicit
3,4-MethylenedioxyamphetamineMagnesium carbonate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental, Illicit
3,4-MethylenedioxymethamphetamineMagnesium carbonate may decrease the excretion rate of 3,4-Methylenedioxymethamphetamine which could result in a higher serum level.Experimental, Illicit
4-AndrostenedioneThe bioavailability of 4-Androstenedione can be decreased when combined with Magnesium carbonate.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineMagnesium carbonate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental, Illicit
5-androstenedioneThe bioavailability of 5-androstenedione can be decreased when combined with Magnesium carbonate.Experimental, Illicit
AcepromazineMagnesium carbonate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AceprometazineMagnesium carbonate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlclometasoneThe bioavailability of Alclometasone can be decreased when combined with Magnesium carbonate.Approved
AldosteroneThe bioavailability of Aldosterone can be decreased when combined with Magnesium carbonate.Experimental
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium carbonate.Approved
AlimemazineMagnesium carbonate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AllopurinolMagnesium carbonate can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmcinonideThe bioavailability of Amcinonide can be decreased when combined with Magnesium carbonate.Approved
AmphetamineMagnesium carbonate may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Illicit
AnecortaveThe bioavailability of Anecortave can be decreased when combined with Magnesium carbonate.Investigational
AtazanavirMagnesium carbonate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Magnesium carbonate.Approved
BeclomethasoneThe bioavailability of Beclomethasone can be decreased when combined with Magnesium carbonate.Investigational
Beclomethasone dipropionateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magnesium carbonate.Approved, Investigational
BenzphetamineMagnesium carbonate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Illicit
BetamethasoneThe bioavailability of Betamethasone can be decreased when combined with Magnesium carbonate.Approved, Vet Approved
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Magnesium carbonate.Approved
Bismuth SubcitrateThe therapeutic efficacy of Bismuth Subcitrate can be decreased when used in combination with Magnesium carbonate.Approved
BL-1020Magnesium carbonate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Magnesium carbonate.Approved
BudesonideThe bioavailability of Budesonide can be decreased when combined with Magnesium carbonate.Approved
CaptoprilThe serum concentration of Captopril can be decreased when it is combined with Magnesium carbonate.Approved
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Magnesium carbonate.Approved
CefpodoximeThe serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium carbonate.Approved, Vet Approved
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Magnesium carbonate.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Magnesium carbonate.Withdrawn
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Magnesium carbonate.Approved, Vet Approved
ChlorphentermineMagnesium carbonate may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Illicit, Withdrawn
ChlorpromazineMagnesium carbonate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ChlortetracyclineMagnesium carbonate can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CiclesonideThe bioavailability of Ciclesonide can be decreased when combined with Magnesium carbonate.Approved, Investigational
CinoxacinMagnesium carbonate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
CiprofloxacinMagnesium carbonate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ClobetasolThe bioavailability of Clobetasol can be decreased when combined with Magnesium carbonate.Investigational
Clobetasol propionateThe bioavailability of Clobetasol propionate can be decreased when combined with Magnesium carbonate.Approved
ClocortoloneThe bioavailability of Clocortolone can be decreased when combined with Magnesium carbonate.Approved
ClodronateThe serum concentration of Clodronate can be decreased when it is combined with Magnesium carbonate.Approved, Investigational, Vet Approved
Coenzyme Q10The serum concentration of Coenzyme Q10 can be decreased when it is combined with Magnesium carbonate.Experimental
Cortisone acetateThe bioavailability of Cortisone acetate can be decreased when combined with Magnesium carbonate.Approved
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Magnesium carbonate.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium carbonate.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Magnesium carbonate.Approved
DasatinibMagnesium carbonate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Magnesium carbonate.Approved
dehydroepiandrosterone sulfateThe bioavailability of dehydroepiandrosterone sulfate can be decreased when combined with Magnesium carbonate.Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Magnesium carbonate.Approved
DemeclocyclineMagnesium carbonate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesoximetasoneThe bioavailability of Desoximetasone can be decreased when combined with Magnesium carbonate.Approved
Desoxycorticosterone acetateThe bioavailability of Desoxycorticosterone acetate can be decreased when combined with Magnesium carbonate.Approved
Desoxycorticosterone PivalateThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Magnesium carbonate.Experimental, Vet Approved
DexamethasoneThe bioavailability of Dexamethasone can be decreased when combined with Magnesium carbonate.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe bioavailability of Dexamethasone isonicotinate can be decreased when combined with Magnesium carbonate.Vet Approved
DexmethylphenidateMagnesium carbonate can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
DextroamphetamineMagnesium carbonate may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved, Illicit
DiethylpropionMagnesium carbonate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Illicit
DiflorasoneThe bioavailability of Diflorasone can be decreased when combined with Magnesium carbonate.Approved
DifluocortoloneThe bioavailability of Difluocortolone can be decreased when combined with Magnesium carbonate.Approved
DifluprednateThe bioavailability of Difluprednate can be decreased when combined with Magnesium carbonate.Approved
Dipotassium phosphateMagnesium carbonate can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DoxycyclineMagnesium carbonate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Magnesium carbonate.Approved
EnoxacinMagnesium carbonate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EquileninThe bioavailability of Equilenin can be decreased when combined with Magnesium carbonate.Experimental
EquilinThe bioavailability of Equilin can be decreased when combined with Magnesium carbonate.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Magnesium carbonate.Approved, Investigational
EstroneThe bioavailability of Estrone can be decreased when combined with Magnesium carbonate.Approved
Estrone sulfateThe bioavailability of Estrone sulfate can be decreased when combined with Magnesium carbonate.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Magnesium carbonate.Approved
Ferric CarboxymaltoseMagnesium carbonate can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitrateMagnesium carbonate can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateMagnesium carbonate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Magnesium carbonate.Approved
FleroxacinMagnesium carbonate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
fluasteroneThe bioavailability of fluasterone can be decreased when combined with Magnesium carbonate.Investigational
FludrocortisoneThe bioavailability of Fludrocortisone can be decreased when combined with Magnesium carbonate.Approved
FlumequineMagnesium carbonate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlumethasoneThe bioavailability of Flumethasone can be decreased when combined with Magnesium carbonate.Approved, Vet Approved
FlunisolideThe bioavailability of Flunisolide can be decreased when combined with Magnesium carbonate.Approved, Investigational
Fluocinolone AcetonideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magnesium carbonate.Approved, Investigational, Vet Approved
FluocinonideThe bioavailability of Fluocinonide can be decreased when combined with Magnesium carbonate.Approved, Investigational
FluocortoloneThe bioavailability of Fluocortolone can be decreased when combined with Magnesium carbonate.Approved, Withdrawn
FluorometholoneThe bioavailability of Fluorometholone can be decreased when combined with Magnesium carbonate.Approved
FluphenazineMagnesium carbonate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluprednideneThe bioavailability of Fluprednidene can be decreased when combined with Magnesium carbonate.Approved, Withdrawn
FluprednisoloneThe bioavailability of Fluprednisolone can be decreased when combined with Magnesium carbonate.Approved
FlurandrenolideThe bioavailability of Flurandrenolide can be decreased when combined with Magnesium carbonate.Approved
Fluticasone furoateThe bioavailability of Fluticasone furoate can be decreased when combined with Magnesium carbonate.Approved
Fluticasone PropionateThe bioavailability of Fluticasone Propionate can be decreased when combined with Magnesium carbonate.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Magnesium carbonate.Approved
FormestaneThe bioavailability of Formestane can be decreased when combined with Magnesium carbonate.Approved, Investigational, Withdrawn
FosinoprilThe serum concentration of Fosinopril can be decreased when it is combined with Magnesium carbonate.Approved
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Magnesium carbonate.Approved, Investigational
GarenoxacinMagnesium carbonate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinMagnesium carbonate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Magnesium carbonate.Approved, Investigational
GemifloxacinMagnesium carbonate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GrepafloxacinMagnesium carbonate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
HE3286The bioavailability of HE3286 can be decreased when combined with Magnesium carbonate.Investigational
HexamethylenetetramineThe therapeutic efficacy of Hexamethylenetetramine can be decreased when used in combination with Magnesium carbonate.Approved, Vet Approved
HydrocortisoneThe bioavailability of Hydrocortisone can be decreased when combined with Magnesium carbonate.Approved, Vet Approved
HydroxyamphetamineMagnesium carbonate may decrease the excretion rate of Hydroxyamphetamine hydrobromide which could result in a higher serum level.Approved
HyoscyamineThe serum concentration of Hyoscyamine can be decreased when it is combined with Magnesium carbonate.Approved
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium carbonate.Approved, Investigational
IronMagnesium carbonate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranMagnesium carbonate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateMagnesium carbonate can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsoniazidMagnesium carbonate can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IstaroximeThe bioavailability of Istaroxime can be decreased when combined with Magnesium carbonate.Investigational
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Magnesium carbonate.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Magnesium carbonate.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Magnesium carbonate.Approved
LevofloxacinMagnesium carbonate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LisdexamfetamineMagnesium carbonate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
LomefloxacinMagnesium carbonate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Magnesium carbonate.Approved, Investigational
ME-609The bioavailability of ME-609 can be decreased when combined with Magnesium carbonate.Investigational
MecamylamineThe serum concentration of Mecamylamine can be increased when it is combined with Magnesium carbonate.Approved
MedrysoneThe bioavailability of Medrysone can be decreased when combined with Magnesium carbonate.Approved
MelengestrolThe bioavailability of Melengestrol can be decreased when combined with Magnesium carbonate.Vet Approved
MemantineThe serum concentration of Memantine can be increased when it is combined with Magnesium carbonate.Approved, Investigational
MephedroneMagnesium carbonate may decrease the excretion rate of Mephedrone which could result in a higher serum level.Investigational
MephentermineMagnesium carbonate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Magnesium carbonate.Approved
MesoridazineMagnesium carbonate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethamphetamineMagnesium carbonate may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved, Illicit
MethotrimeprazineMagnesium carbonate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Methylene blueMagnesium carbonate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
MethylphenidateMagnesium carbonate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylprednisoloneThe bioavailability of Methylprednisolone can be decreased when combined with Magnesium carbonate.Approved, Vet Approved
MevastatinThe serum concentration of Mevastatin can be decreased when it is combined with Magnesium carbonate.Experimental
MinocyclineMagnesium carbonate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MisoprostolThe risk or severity of adverse effects can be increased when Magnesium carbonate is combined with Misoprostol.Approved
MMDAMagnesium carbonate may decrease the excretion rate of MMDA which could result in a higher serum level.Experimental, Illicit
MometasoneThe bioavailability of Mometasone can be decreased when combined with Magnesium carbonate.Approved, Vet Approved
MoricizineMagnesium carbonate can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
MoxifloxacinMagnesium carbonate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Mycophenolic acidMagnesium carbonate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Nalidixic AcidMagnesium carbonate can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NCX 1022The bioavailability of NCX 1022 can be decreased when combined with Magnesium carbonate.Investigational
NemonoxacinMagnesium carbonate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Magnesium carbonate.Approved, Investigational
NorfloxacinMagnesium carbonate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OfloxacinMagnesium carbonate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Oleoyl estroneThe bioavailability of Oleoyl estrone can be decreased when combined with Magnesium carbonate.Investigational
OxytetracyclineMagnesium carbonate can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Magnesium carbonate.Approved
ParamethasoneThe bioavailability of Paramethasone can be decreased when combined with Magnesium carbonate.Approved
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Magnesium carbonate.Approved
PazufloxacinMagnesium carbonate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinMagnesium carbonate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenicillamineThe serum concentration of Penicillamine can be decreased when it is combined with Magnesium carbonate.Approved
PerazineMagnesium carbonate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PerphenazineMagnesium carbonate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PhentermineMagnesium carbonate may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Illicit
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Magnesium carbonate.Approved
Polystyrene sulfonateThe risk or severity of adverse effects can be increased when Magnesium carbonate is combined with Polystyrene sulfonate.Approved
PrasteroneThe bioavailability of Prasterone can be decreased when combined with Magnesium carbonate.Approved, Nutraceutical
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Magnesium carbonate.Approved
PrednicarbateThe bioavailability of Prednicarbate can be decreased when combined with Magnesium carbonate.Approved
PrednisoloneThe bioavailability of Prednisolone can be decreased when combined with Magnesium carbonate.Approved, Vet Approved
PrednisoneThe bioavailability of Prednisone can be decreased when combined with Magnesium carbonate.Approved, Vet Approved
PregnenoloneThe bioavailability of Pregnenolone can be decreased when combined with Magnesium carbonate.Experimental
ProchlorperazineMagnesium carbonate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromazineMagnesium carbonate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromethazineMagnesium carbonate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PropiopromazineMagnesium carbonate can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
PrulifloxacinMagnesium carbonate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PseudoephedrineMagnesium carbonate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
QuinidineMagnesium carbonate may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Magnesium carbonate.Approved
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Magnesium carbonate.Approved
RimexoloneThe bioavailability of Rimexolone can be decreased when combined with Magnesium carbonate.Approved
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Magnesium carbonate.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Magnesium carbonate.Approved, Investigational
RitobegronMagnesium carbonate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Investigational
RosoxacinMagnesium carbonate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Magnesium carbonate.Approved
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Magnesium carbonate.Approved
Sodium glycerophosphateMagnesium carbonate can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphatesMagnesium carbonate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Magnesium carbonate.Approved
SparfloxacinMagnesium carbonate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SulpirideThe serum concentration of Sulpiride can be decreased when it is combined with Magnesium carbonate.Approved
Technetium tc 99m etidronateThe serum concentration of Technetium tc 99m etidronate can be decreased when it is combined with Magnesium carbonate.Approved
Technetium Tc-99m MedronateThe serum concentration of Technetium Tc-99m Medronate can be decreased when it is combined with Magnesium carbonate.Approved
TemafloxacinMagnesium carbonate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
TetracyclineMagnesium carbonate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ThiethylperazineMagnesium carbonate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThioridazineMagnesium carbonate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Tiludronic acidThe serum concentration of Tiludronate can be decreased when it is combined with Magnesium carbonate.Approved, Vet Approved
TixocortolThe bioavailability of Tixocortol can be decreased when combined with Magnesium carbonate.Approved
TriamcinoloneThe bioavailability of Triamcinolone can be decreased when combined with Magnesium carbonate.Approved, Vet Approved
TriethylenetetramineMagnesium carbonate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TrifluoperazineMagnesium carbonate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TriflupromazineMagnesium carbonate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TrovafloxacinMagnesium carbonate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Magnesium carbonate.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External LinksNot Available
ATC CodesV03AE04A02AA01A06AD01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentHealthy Volunteers1
1RecruitingBasic ScienceGastroEsophageal Reflux Disease1
4CompletedTreatmentDyspepsia / Emergency / Pain1
Not AvailableCompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
Properties
StateNot Available
Experimental PropertiesNot Available
Predicted PropertiesNot Available
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Taxonomy
ClassificationNot classified
Comments
comments powered by Disqus
Drug created on November 30, 2015 12:10 / Updated on August 17, 2016 12:24